SCHEMBL538877

SCHEMBL538877

CCOc1ccc(O)c(C(=O)O)c1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.54
ALDH1A1 P00352 4/20 0.54
HPGD P15428 4/20 0.54
HSD17B10 Q99714 4/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
CYP1A2 P05177 1/20 0.54
TSHR P16473 1/20 0.54
MCL1 Q07820 3/20 0.53
FADS1 O60427 1/20 0.53
CSNK2A1 P68400 1/20 0.52
MAPT P10636 2/20 0.50
ALOX15 P16050 2/20 0.50
RECQL P46063 2/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
ALOX5 P09917 1/20 0.50
PTGS2 P35354 1/20 0.50
CA7 P43166 1/20 0.50
CA9 Q16790 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29670829 1.00 KDM4E (0.54) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL29623897 0.86 MCL1 (0.69) TSHRMCL1TP53
SCHEMBL538445 0.86 MCL1 (0.61) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL1576849 0.86 MCL1 (0.69) TSHRMCL1TP53
SCHEMBL539138 0.86 ALDH1A1 (0.55) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL3652542 0.86 MAOB (0.61) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL930228 0.85 ALDH1A1 (0.59) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL9285957 0.83 MCL1 (0.66) TSHRMCL1TP53
SCHEMBL4579370 0.83 POLB (0.53) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL10469566 0.83 CA12 (0.68) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0987011-B1 Cosmetic and/or dermatological composition containing salicylic acid or its derivatives and its use OREAL (FR) 2002-07-17 EP claimed
US-6281203-B1 ESTER OF A FATTY ACID AND GLUCOSE AND/OR ALKYLGLUCOSE, AND AN OXYETHYLENATED ETHER OF A FATTY ACID ESTER OF GLUCOSE AND/OR ALKYLGLUCOSE. L'OREAL (FR) 2001-08-28 US claimed
EP-3389595-B1 COMBINATION OF POLYION COMPLEX PARTICLE AND NON-POLYMERIC ACID HAVING TWO OR MORE ACID DISSOCIATION CONSTANTS OREAL (FR) 2025-11-05 EP disclosed
US-20250214920-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND KAO CORPORATION (JP) 2025-07-03 US disclosed
EP-3638192-B1 COMBINATION OF POLYION COMPLEX PARTICLE AND NON-POLYMERIC ACID OR BASE HAVING TWO OR MORE DISSOCIATION CONSTANTS OREAL (FR) 2025-04-02 EP disclosed
CN-119591637-A Compound with aryl amide structure and medical application thereof 南京芩领医药科技有限公司 2025-03-11 CN disclosed
EP-3638201-B1 COMBINATION OF POLYION COMPLEX PARTICLE AND NON-POLYMERIC BASE HAVING TWO OR MORE DISSOCIATION CONSTANTS OREAL (FR) 2025-02-26 EP disclosed
EP-4501896-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND Kao Corporation (JP) 2025-02-05 EP disclosed
EP-4501897-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND Kao Corporation (JP) 2025-02-05 EP disclosed
CN-118973991-A Process for producing cyclic diketone compound 花王株式会社 2024-11-15 CN disclosed
CN-118973990-A Process for producing cyclic diketone compound 花王株式会社 2024-11-15 CN disclosed
EP-0714785-B1 Sulfonated phenol (salt) containing color-developing agents and color-developing sheets MITSUI CHEMICALS INC (JP) 1999-01-07 EP disclosed
EP-0570230-B1 External preparation for skin SHISEIDO CO LTD (JP) 1998-09-30 EP disclosed
EP-0659580-B1 Polyvalent metal salt of salicylic acid resin and process for preparing it MITSUI TOATSU CHEMICALS (JP) 1997-08-20 EP disclosed
US-5647896-A MULTIVALENT SALT OF A SALICYLIC ACID DERIVATIVE, SULFONATED PHENOL MITSUI TOATSU CHEMICALS, INC. (JP) 1997-07-15 US disclosed
US-5580549-A BLEACHING; 2-HYDROXYBENZOIC ACID COMPOUND SHISEIDO CO., LTD. (JP) 1996-12-03 US disclosed
US-5525686-A Polyvalent metal salt of salicyclic acid resin and process for preparing it MITSUI TOATSU CHEMICALS, INC. (JP) 1996-06-11 US disclosed
EP-0714785-A1 Sulfonated phenol (salt) containing color-developing agents and color-developing sheets MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1996-06-05 EP disclosed
EP-0659580-A1 Polyvalent metal salt of salicylic acid resin and process for preparing it MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1995-06-28 EP disclosed
EP-0570230-A1 External preparation for skin SHISEIDO COMPANY LIMITED (JP) 1993-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214920-A1 METHOD FOR PRODUCING CYCLIC DIKETONE COMPOUND CYP4F2, DUOX1, BCKDK KDM4E 1578/4885ALDH1A1 973/4885HPGD 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.